Several other equities analysts have also recently commented on AMED. Credit Suisse Group decreased their price target on shares of Amedisys from $200.00 to $195.00 and set an outperform rating for the company in a research report on Friday, February 25th. StockNews.com assumed coverage on shares of Amedisys in a research report on Thursday, March 31st. They set a hold rating for the company. Truist Financial decreased their price objective on shares of Amedisys from $200.00 to $175.00 and set a buy rating for the company in a research report on Tuesday. SVB Leerink decreased their price objective on shares of Amedisys from $131.00 to $117.00 and set a market perform rating for the company in a research report on Friday, May 27th. Finally, UBS Group raised shares of Amedisys from a sell rating to a neutral rating and lifted their price objective for the stock from $152.00 to $168.00 in a research report on Tuesday, March 1st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, Amedisys currently has an average rating of Moderate Buy and a consensus target price of $173.27.
NASDAQ:AMED opened at $115.28 on Tuesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.03 and a current ratio of 1.03. The stock has a market capitalization of $3.76 billion, a P/E ratio of 19.84, a PEG ratio of 2.10 and a beta of 0.89. The company has a 50 day moving average price of $122.52 and a 200 day moving average price of $142.33. Amedisys has a fifty-two week low of $101.61 and a fifty-two week high of $276.21.
In other news, insider David L. Kemmerly sold 2,500 shares of the business’s stock in a transaction dated Tuesday, March 29th. The shares were sold at an average price of $177.31, for a total transaction of $443,275.00. Following the transaction, the insider now directly owns 16,336 shares in the company, valued at $2,896,536.16. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.10% of the company’s stock.
Several institutional investors have recently modified their holdings of AMED. Riverbridge Partners LLC increased its stake in shares of Amedisys by 57.0% during the fourth quarter. Riverbridge Partners LLC now owns 1,588,750 shares of the health services provider’s stock worth $257,187,000 after acquiring an additional 576,633 shares during the period. Mackenzie Financial Corp increased its stake in shares of Amedisys by 39,235.8% during the fourth quarter. Mackenzie Financial Corp now owns 570,369 shares of the health services provider’s stock worth $92,331,000 after acquiring an additional 568,919 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in Amedisys during the fourth quarter worth about $85,286,000. JPMorgan Chase & Co. boosted its holdings in Amedisys by 23.5% during the first quarter. JPMorgan Chase & Co. now owns 1,384,041 shares of the health services provider’s stock worth $238,457,000 after buying an additional 263,275 shares in the last quarter. Finally, Bellevue Group AG boosted its holdings in Amedisys by 61.8% during the fourth quarter. Bellevue Group AG now owns 490,012 shares of the health services provider’s stock worth $79,323,000 after buying an additional 187,214 shares in the last quarter. Institutional investors and hedge funds own 90.47% of the company’s stock.
Amedisys Company Profile (Get Rating)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
- Get a free copy of the StockNews.com research report on Amedisys (AMED)
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.